The cell-death activator gene
egl-1 ( egl , eg g- l aying defective) acts as a negative regulator of the cell-death inhibitor gene
ced-9 and is the most upstream acting component of the central pathway required for programmed cell death in the C. elegans soma.
egl-1 encodes a BH3-containing protein, which has been proposed to activate cell death by binding to and thereby negatively regulating the Bcl-2-like CED-9 protein (1). A loss-of-function mutation in
egl-1 blocks most if not all somatic cell deaths that occur during development. This mutation is a five bp deletion in the coding region of
egl-1 and results in the formation of a truncated EGL-1 protein (1). Dominant gain-of-function mutations in the
egl-1 gene, by contrast, result in ectopic cell death:
egl-1 (gf) mutations cause the activation of the cell-death pathway in the HSNs (HSN, h ermaphrodite- s pecific n euron) not only in males but also in hermaphrodites, in which the HSNs normally survive (2). The
egl-1 (gf) mutations are single-base changes within a putative binding site for TRA-1 (TRA, transformer), the terminal and global regulator of somatic sex (3). This site is located 5.6 kb downstream of the
egl-1 transcription unit. TRA-1 binds to this site in vitro , and this binding is disrupted by the introduction of the
egl-1 (gf) mutations. We propose that TRA-1 acts as a repressor of
egl-1 transcription in the HSNs to ensure the survival of these neurons in hermaphrodites. This hypothesis is supported by our finding that the
tra-1 gene determines the cell-death fate of the HSNs in an
egl-1 -dependent manner. 1. Conradt, B. and H. R. Horvitz. (1998). Cell 93 , 519-529. 2. Trent, C., Tsung, N., and H. R. Horvitz. (1983). Genetics 104 , 619-647. 3. Zarkower, D. and Hodgkin, J. (1992). Cell 70 , 237-269.